TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A November 5 commentary by six clinicians and researchers argues that chronic neuropathic pain after intensive care may receive too little attention and calls for earlier, more specific diagnosis. Neuromodulation is a possible research direction for selected patients, but the authors say direct evidence in ICU survivors is insufficient to establish its effectiveness.
A commentary published November 5 by six clinicians and researchers says chronic neuropathic pain in intensive care unit (ICU) survivors deserves more specific recognition, while stressing that not all pain after critical illness comes from nerve damage. The authors argue that diagnosis should improve before neuromodulation is considered as a possible option for carefully selected patients; they say evidence directly testing such approaches in this group remains insufficient.
The authors describe persistent pain as one part of the difficulties some people face after critical illness, alongside weakness, limited mobility, sleep problems, cognitive difficulties and psychological distress. They cite a systematic review reporting persistent pain frequencies of 28% to 77%, a range they attribute to differences in populations, definitions and follow-up periods. A 2026 meta-analysis they reference estimated chronic pain incidence at about 47% at three months, 29% at six months and 31% at 12 months.
Those figures cover chronic pain generally, not neuropathic pain alone. In a prospective multicenter cohort of 814 patients, nearly 48% reported significant persistent pain three months after ICU admission. Among patients reporting pain, about 9% screened positive for neuropathic symptoms. A positive screen is not, by itself, proof of a particular nerve disorder, and the authors caution against labeling all post-ICU pain as neuropathic.
The commentary says pain can have different causes, including muscle injury, procedures, immobility and deconditioning, as well as peripheral nerve injury or critical illness polyneuropathy. Weakness by itself does not establish neuropathic pain. The authors recommend matching evaluation and treatment to the suspected source, with rehabilitation, physical therapy, psychological support, sleep care and individualized medication management remaining part of recovery.
Why Correct Pain Diagnosis Matters
Separating nerve-related pain from muscle, joint or other causes matters because the treatment approach may differ. The authors note that medications used for some neuropathic pain presentations, including gabapentinoids and certain antidepressants, can be difficult for some recovering patients to tolerate. They cite concerns such as renal dysfunction, cognitive impairment, dizziness, sedation and respiratory vulnerability. The commentary does not recommend stopping or changing medication; it argues for individualized care rather than assuming that increasing medication is always the answer.
Persistent pain can also interfere with rehabilitation and daily recovery. For patients whose confirmed neuropathic pain remains disabling despite appropriate conventional care, the authors say targeted therapies warrant investigation. Their proposal is a research framework, not evidence that a particular device will help ICU survivors. Clear diagnosis and well-designed studies are needed before clinicians can judge potential benefits and risks for this population.
Products Worth Considering
Shark HydroVac MessMaster Wet/Dry Vacuum & Mop Combo (AW261)
Roborock Q7 L5 Robot Vacuum and Mop Combo
Levoit Eleva 300X Air Purifier with Sealed HEPA Filtration
As an affiliate, we earn on qualifying purchases.
Neuromodulation Evidence Has Limits
The authors’ narrative review, titled Neuromodulation for Refractory Neuropathic Pain Following Critical Illness: A Narrative Review and Phenotype-Based Clinical Framework, considers peripheral nerve stimulation (PNS), dorsal root ganglion stimulation (DRGS) and spinal cord stimulation (SCS). These technologies target different parts of the nervous system. The review suggests studying PNS for localized nerve injuries, DRGS for selected regional pain patterns, and SCS for some bilateral or multisegmental neuropathic pain presentations, provided the diagnosis and treatment target are established.
The commentary points to trials in other conditions as reasons for research interest, not proof of effectiveness after critical illness. It cites the ACCURATE trial, which found higher three-month treatment success with DRGS than conventional SCS among patients with lower-extremity complex regional pain syndrome or causalgia, and the SENZA-PDN trial of 10-kHz SCS in refractory painful diabetic neuropathy. Those trial populations differ from ICU survivors; results cannot simply be transferred to them.
“We need to identify neuropathic pain earlier, understand its underlying mechanisms, and investigate treatment strategies beyond conventional pharmacotherapy when symptoms remain disabling.”
— Suresh Srinivasan, Kiran Khurshid, Uzam Hussain, Joseph Pathakamuri and Mohanraj Palani Selvam, authors of the MedPage Today commentary
Evidence in ICU Survivors Remains Sparse
The commentary does not establish how many ICU survivors have confirmed chronic neuropathic pain. The cited cohort reports the share who screened positive for neuropathic symptoms among people with persistent pain, not a definitive diagnosis rate for all survivors. Estimates also vary across studies, and the cited figures use different time points and measures.
Most importantly, the supplied report says there is insufficient direct clinical evidence to establish the effectiveness of neuromodulation for neuropathic pain following critical illness. It does not provide a treatment recommendation for individual patients, nor does it establish which survivors might benefit, what risks devices could pose in this group, or how outcomes would compare with usual care.
Diagnosis and Research Come First
The authors call for earlier identification of nerve-related symptoms, better understanding of the mechanisms behind them and research into treatment options for patients who remain disabled despite conventional care. Their phenotype-based framework is intended to guide investigation of which stimulation approach might fit particular patterns of nerve pain.
The commentary does not announce a clinical trial, timeline or change to standard care. For now, its proposed next step is more precise assessment and direct study of neuromodulation in appropriately selected ICU survivors. Whether those studies will show meaningful benefit, and for which patients, remains unknown.
Key Questions
How common is chronic pain after an ICU stay?
The commentary cites a 2026 meta-analysis estimating chronic pain incidence at about 47% at three months, 29% at six months and 31% at 12 months. Estimates vary by study and do not mean all of this pain is neuropathic.
Does persistent pain after critical illness mean nerve damage?
No. The authors describe possible causes including muscle injury, procedures, immobility and deconditioning, as well as nerve injury. They say weakness alone should not be treated as evidence of neuropathic pain.
Is neuromodulation proven to treat pain in ICU survivors?
No. The commentary discusses PNS, DRGS and SCS as possible research directions, but says direct clinical evidence in people recovering from critical illness is insufficient to establish effectiveness.
What does the cited 9% figure refer to?
In a prospective cohort of 814 patients, about 9% of those reporting persistent pain screened positive for neuropathic pain symptoms three months after ICU admission. It was a screening result, not a confirmed diagnosis rate among all ICU survivors.
Source: medpagetoday.com
